Compare e l f Beauty Inc (ELF) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Zoetis Inc — how do they compare? e l f Beauty Inc trades at $94.2 (market cap $5.61B), while Zoetis Inc trades at $73.15 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 5.6× e l f Beauty Inc's market cap, and Zoetis Inc pays a 2.81% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.
| ELF | ZTS | |
|---|---|---|
Market Cap | $5.61B | $31.14B |
Sector | Technology | Health |
52-Week High | $146.67 | $156.76 |
52-Week Low | $49.57 | $71.91 |
Enterprise Value | $6.19B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $94.33, down 0.96% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2027 results, beating EPS estimates with $1.75 versus $0.71 expected, driven by 36% sales growth from the Rhode brand and international expansion. Valuation metrics show a high P/E of 96.93, reflecting premium pricing for growth. Recent news highlights a $50 million tariff refund boosting profits and expansion into hair care products.
Outlook remains positive due to consistent revenue growth and raised guidance, but risks include high valuation dependence on acquisitions and organic unit declines. Analyst consensus is mixed with a $91.14 price target, suggesting cautious optimism amid execution risks.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
